⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099106 | 1.00 | TRIM24 (0.41) | — | |
| SCHEMBL9171769 | 0.96 | TRIM24 (0.44) | — | |
| SCHEMBL136359 | 0.87 | TRIM24 (0.44) | — | |
| SCHEMBL5110848 | 0.87 | TRIM24 (0.44) | — | |
| SCHEMBL3915558 | 0.86 | MEN1 (0.33) | — | |
| SCHEMBL515266 | 0.84 | TRIM24 (0.47) | — | |
| SCHEMBL515401 | 0.84 | TRIM24 (0.47) | — | |
| SCHEMBL25225227 | 0.80 | — | — | |
| SCHEMBL31715737 | 0.80 | GAA (0.33) | — | |
| SCHEMBL15422328 | 0.80 | TRIM24 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090348-A1 | THE USE OF SON OF SEVENLESS (SOS) INHIBITOR COMPOUNDS SUCH AS 7-SUBSTITUTED BENZOFURANS TO TREAT CANCER | Mirati Therapeutics, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12410208-B2 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-09 | — | — | US | disclosed |
| US-20250276090-A1 | Methods and Compositions for Genetically Modifying a Cell | INTELLIA THERAPEUTICS, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIOVENTURES, INC., | 2025-07-10 | — | — | US | disclosed |
| US-20250205244-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250186436-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | 4E THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4540383-A1 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING A CELL | Intellia Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-1910364-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008007930-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1598350-B1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | SERVIER LAB (FR) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007011833-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1598350-A1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | LES LABORATOIRES SERVIER (FR) | 2005-11-23 | — | — | EP | disclosed |
| US-5471003-A | Catalytic hydrogenation then distillation to remove butyraldehyde | EASTMAN CHEMICAL COMPANY (US) | 1995-11-28 | — | — | US | disclosed |